Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (809)	5/21/1998 11:00:00 PM
From: SOROS	Read Replies (2) \| Respond to of 1185

I'm sure everyone has seen this, but I do like it (from Nortran's website): "The company's scientists have focused their expertise on ion channel function in two therapeutic areas where ion channels are involved, namely the prevention of life-threatening heart malfunctions, and the treatment of pain. Nortran is clearly unique amongst small companies in North America in its platform technology. Its research capabilities are more similar to those of the multinational pharmaceutical companies than to those of the small biotechnology companies. On the other hand, many of the multinational companies are either downsizing their drug discovery programs or moving toward biotechnology approaches (molecular targeting, combinatorial chemistry/high throughput screening), making Nortran even more unique in its platform technology. The potential for Nortran's products to revolutionize the treatment of heart disease and pain is enormous. Nortran Pharmaceuticals has the potential to become a giant in the pharmaceutical industry." I remain, SOROS ps This is not meant to hype (as accusations have been FALSELY made). The "hype" has all been negative, persistent, dragged out over multiple posts, and unrelenting. I just want to encourage those of us that ALREADY own the stock. Nothing more. Nothing less.